Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
By Region : North America Europe APAC Latin America MEA Asia Pacific held a sizable revenue share in the global GLP-1 receptor agonist market and is set to witness substantial development by 2032, attributed to the rising prevalence of diabetes driven by factors, such as changing lifestyles, unhealthy diets, and sedentary habits, which is contributing to the increasing demand for effective diabetes management drugs
Pharmacological approaches able to promote healthy incretin and insulin signaling in the brain may represent a potential direction for neurodegenerative disease treatment
Retrieved from Safwan, M., Bourgleh, M
53045312, Aug
SCFAs may stimulate the release of GLP-1 by binding to the L-cell receptors
